Wegovy gets EU regulator backing on lowering heart risks in obese people
The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic.
HQ Team July 16, 2024: A new animal study has found a new therapy that is able to boost inuslin-producing cells by 700%.
Israel’s Teva Pharmaceuticals will start selling a generic version of Novo Nordisk’s type 2 diabetic drug Victoza in the US market.
The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA refused approval for a once-weekly jab to control blood sugar levels in people.
Research finds a sharp increase in use of weightloss drugs such as Ozempic and Wegovy among teens and young adults
HQ Team March 21, 2024: Richard Slayman, 62, of Weymouth, Massachusetts, became the first human to receive a kidney from a genetically modified.
HQ Team March 11, 2024: Danish drugmaker Novo Nordisk’s oral medicine, amycretin, for obesity can cause up to 13% weight loss, the company.
HQ Team March 6, 2024: Novo Nordisk’s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney death in 24%.
HQ Team January 9, 2023: Denmark’s Novo Nordisk declared its late-stage experimental once-weekly diabetes drug IcoSema achieved its primary endpoint of proving “non-inferiority” in.
HQ Team December 13, 2023: Vertex Pharmaceuticals, a US-based biotechnology company, announced its mid-stage trial on a non-opioid oral drug for patients with.